Improving radiation therapy access for Black breast and prostate cancer patients
Prospective Pilot Study of Navigator-Assisted Hypofractionation (NAVAH) Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer Patients
This study is trying to see if helping Black patients with breast and prostate cancer get better access to radiation therapy can improve their treatment completion rates and health outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Cleveland, Ohio) |
| Trial ID | NCT05978232 on ClinicalTrials.gov |
What this trial studies
This study aims to address the disparities in access to radiation therapy for African-American patients diagnosed with breast and prostate cancer. It focuses on the implementation of a navigator-assisted hypofractionation approach to ensure these patients receive the standard-of-care treatment they need. By identifying barriers and providing support, the study seeks to improve completion rates of radiation therapy among this population. The research is crucial given the higher cancer death rates and shorter survival times experienced by African-Americans.
Who should consider this trial
Good fit: Ideal candidates for this study are African-American adults aged 18 and older with histologically or cytologically confirmed breast or prostate cancer.
Not a fit: Patients who are not of African-American ethnicity or do not have confirmed breast or prostate cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve access to and completion of radiation therapy for African-American breast and prostate cancer patients.
How similar studies have performed: Previous studies have indicated that addressing access disparities can lead to improved outcomes, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects must have histologically or cytologically confirmed Breast or Prostate Cancer. * Subjects must be Age \>18 years. This study requires informed consent by the subject; as children are not able to perform this without parental approval, subjects \< age 18 are excluded from this study. * Subjects must be of African - American race. * Subjects must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Subjects NOT of African - American ethnicity. * Subjects WITHOUT histologically or cytologically confirmed Breast or Prostate Cancer.
Where this trial is running
Cleveland, Ohio
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Shearwood McClelland III, MD — University Hospitals Cleveland Medical Center Seidman Cancer Center
- Study coordinator: Shearwood McClelland III, MD
- Email: Shearwood.mcclelland@uhhospitals.org
- Phone: 216-702-8700
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.